Ke Yan

Ke Yan, CFA, FRM, is an accomplished equity research analyst with a strong passion for investment strategies in Asia Pacific, backed by eight years of diverse sector coverage experience.

He has showcased a specialized focus on Chinese biotech listings and data analytics related to Hong Kong/China Connect flows in recent times.

Ke Yan is an advocate for leveraging technology in investment research and has a track record of developing cutting-edge analytical tools for premier institutional investors, including a cloud-based dynamic NaV model for holding companies and a quantitative evaluation framework for ranking top-performing IPOs and Placements in Asia Pacific.

His expert insight has been sought after by prominent international media outlets such as Bloomberg, Thomson Reuters, Wall Street Journal, and Nikkei Asia Review, among others, reflecting his significant influence in the field.

Ke Yan's executive research summary and more information about his work can be found on his profile at Smartkarma.